Cargando…

Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context

BACKGROUND: Survivors from Ebola virus disease (EVD) may be at the origin of EVD resurgence. METHODS: Simultaneous reactivity to at least 2 Ebola virus or Zaire ebolavirus (EBOV) antigens was detected in 11 of 488 (2.3%; 95% confidence interval [CI], 1.1–4.0) suspected EVD patients who were discharg...

Descripción completa

Detalles Bibliográficos
Autores principales: Nkuba-Ndaye, Antoine, Mukadi-Bamuleka, Daniel, Bulabula-Penge, Junior, Thaurignac, Guillaume, Edidi-Atani, François, Mambu-Mbika, Fabrice, Danga-Yema, Bernice, Matondo-Kuamfumu, Meris, Kinganda-Lusamaki, Eddy, Bisento, Nella, Lumembe-Numbi, Raphaël, Kabamba-Lungenyi, Gabriel, Kitsa-Mutsumbirwa, Divine, Kambale-Sivihwa, Nelson, Boillot, François, Delaporte, Eric, Mbala-Kingebeni, Placide, Ayouba, Ahidjo, Peeters, Martine, Ahuka-Mundeke, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400424/
https://www.ncbi.nlm.nih.gov/pubmed/35176762
http://dx.doi.org/10.1093/infdis/jiac057
Descripción
Sumario:BACKGROUND: Survivors from Ebola virus disease (EVD) may be at the origin of EVD resurgence. METHODS: Simultaneous reactivity to at least 2 Ebola virus or Zaire ebolavirus (EBOV) antigens was detected in 11 of 488 (2.3%; 95% confidence interval [CI], 1.1–4.0) suspected EVD patients who were discharged as negative after 2 consecutive negative tests during the 10th Ebola outbreak in the Democratic Republic of the Congo. RESULTS: After extrapolating the total number of individuals discharged as negative during the entire outbreak, we estimated a total of 1314 additional missed Ebola cases. CONCLUSIONS: These findings emphasize the usefulness of an EBOV serology analysis and the importance of extending epidemic surveillance to clinically suspected cases who were discharged as negative.